Dr. Trinity J. Bivalacqua, MD PHD
Urology (Urology Physician)
3400 Civic Center Blvd, West Pavilion 3rd Floor
Philadelphia, PA 19104
- Medicare participating
At a glance
- Medical school
- Tulane University School of Medicine (2004)
- Years since graduation
- 22
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 358
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2004Medical school: Tulane University School of Medicine
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Urology Physician primary
PA license MD475725
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Hospital of Univ of Pennsylvania Philadelphia, PA
- Penn Presbyterian Medical Center Philadelphia, PA
- Chester County Hospital West Chester, PA
- Pennsylvania Hospital Philadelphia, PA
- University Medical Center of Princeton at Plainsboro Plainsboro, NJ
Medical groups
- University of Penn - Medical Group (3,505 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 358
- Services billed
- 860
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Diagnostic exam of bladder and urethra using an endoscope | 172 | 111 |
| Established patient office or other outpatient visit, 20-29 minutes | 118 | 94 |
| New patient office or other outpatient visit, 30-44 minutes | 90 | 90 |
| Established patient office or other outpatient visit, 30-39 minutes | 64 | 55 |
| Destruction and/or removal of growth of bladder and urethra using an endoscope, 2.0-5.0 cm | 51 | 47 |
| Destruction and/or removal of growth of bladder and urethra using an endoscope, 0.5-2.0 cm | 44 | 40 |
| Removal of bladder and lymph nodes on both sides of pelvis with transplantation of ureters to small or large bowel with creation of urinary opening | 25 | 25 |
| Biopsy of bladder using an endoscope | 25 | 25 |
| Removal of prostate | 22 | 22 |
| Ultrasonic guidance for needle placement | 15 | 15 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 4 companies reported 9 payments worth $8,695 in total to this clinician.
| Urogen Pharma, Inc. | $8,397 |
|---|---|
| Pfizer Inc. | $123 |
| Janssen Biotech, Inc. | $117 |
| Baxter Healthcare | $58.65 |
| Consulting Fee | $8,000 |
|---|---|
| Food and Beverage | $695 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Urogen Pharma, Inc. Aug 25, 2025 | Consulting Fee | $8,000 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $5,491 in research payments for these studies, mostly to the institutions running them.
- A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4)
Janssen Research & Development, LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.